Evidence map›Paper›PMID 24613524›Full record

Trial reportVaccine2014

Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Paul V Licciardi, Fiona M Russell, Anne Balloch, Robert L Burton, Moon H Nahm, Gwendolyn Gilbert, Mimi L K Tang, Edward K Mulholland

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Paul V LicciardiPneumococcal Research Group, Australia; Allergy and Immune Disorders Group, Murdoch Childrens Research Institute, Australia. Electronic address: paul.licciardi@mcri.edu.au.
Fiona M RussellPneumococcal Research Group, Australia; Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
Anne BallochPneumococcal Research Group, Australia; Allergy and Immune Disorders Group, Murdoch Childrens Research Institute, Australia.
Robert L BurtonDepartment of Pathology, University of Alabama at Birmingham, USA; Department of Microbiology, University of Alabama at Birmingham, USA.
Moon H NahmDepartment of Pathology, University of Alabama at Birmingham, USA; Department of Microbiology, University of Alabama at Birmingham, USA.
Gwendolyn GilbertWestmead Millennium Institute for Medical Research, University of Sydney, Australia.
Mimi L K TangPneumococcal Research Group, Australia; The Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Edward K MulhollandPneumococcal Research Group, Australia; Menzies School of Health Research, Darwin, Australia; London School of Hygiene and Tropical Medicine, London, United Kingdom.
PYC Therapeutics (Australia) · AUUniversity of Alabama at Birmingham · USUniversity of Melbourne · AUUniversity of Sydney · AU

Funding

Appropriate pneumococcal vaccination in infants in FijiU01AI052337 · NIAID · UNIVERSITY OF MELBOURNE · PI RUSSELL, FIONA · 2005 to 2007
$1.4M
Appropriate Pneumococcal Vaccination in Infants in FijiR01AI052337 · NIAID · UNIVERSITY OF MELBOURNE · PI MULHOLLAND, EDWARD KIM · 2002 to 2005
$1.2M
NIAID NIH HHS 2 U01AI052337-05NIAID NIH HHS N01 AI030021NIAID NIH HHS R01 AI052337NIAID NIH HHS U01 AI052337
6 · The paper itself

Abstract

The impact of prior nasopharyngeal carriage on serotype-specific IgG responses following immunization with pneumococcal conjugate vaccines (PCV) has recently been described. This report extends these findings to describe the attenuation of functional immune responses following 23-valent pneumococcal polysaccharide vaccination (PPS). We report the attenuation of immune responses following booster with the 23-valent pneumococcal polysaccharide vaccination (PPS) in infants with prior nasopharyngeal carriage of Streptococcus pneumoniae. Fijian infants who were part of a phase II randomized, controlled trial of reduced dose PCV7 schedules were the basis of this study. Pneumococcal carriage was determined at 6, 9 and 12 months of age, prior to PPS immunization. Serum samples collected at 18 weeks (post-PCV7), 12 months (pre-PPS), 12.5 months and 17 months (post-PPS) of age were assessed for serotype-specific IgG and opsonophagocytic responses. The most frequently carried serotypes were 6B (N=11), 19F (N=14) and 23F (N=23). Significantly lower serotype-specific IgG for 19F, 23F but not 6B post-PPS were detected in infants with homologous serotype carriage prior to PPS compared with non-carriers (N=230). However, OPA levels for 6B and 23F were lower in infants that carried these serotypes. Pneumococcal carriage with 19F or 23F at any time prior to PPS immunization in infants at 12 months of age who were previously primed with PCV resulted in serotype-specific hyporesponsiveness that persisted until 17 months of age. These results may have implications for the timing of infant vaccine schedules, particularly in high disease burden settings.

Indexed as

Antibody SpecificityAntibodies, BacterialCarrier StateFijiHumansImmunoglobulin GInfantNasopharynxPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerotypingSingle-Blind MethodStreptococcus pneumoniaeTime Factors23-valent pneumococcal capsular polysaccharide vaccineAntibodies, BacterialImmunoglobulin GPneumococcal VaccinesCarriageHyporesponsivenessOpsonophagocytosisPneumococcalPPS

Identifiers

PMID24613524
PMCPMC4019672
OpenAlexW2080172496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.